NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Ascending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68084-0221-11 | 68084-0221 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 3, 2012 | In Use | |
70934-0148-03 | 70934-0148 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 19, 2018 | Nov. 30, 2023 | In Use |
70934-0148-04 | 70934-0148 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug. 6, 2018 | Aug. 31, 2025 | In Use |
70934-0148-05 | 70934-0148 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 29, 2019 | Nov. 30, 2023 | In Use |
70934-0148-06 | 70934-0148 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct. 22, 2018 | Nov. 30, 2023 | In Use |
70934-0148-10 | 70934-0148 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | July 16, 2019 | June 30, 2024 | In Use |
70934-0264-10 | 70934-0264 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 9, 2020 | Jan. 31, 2025 | In Use |
70934-0264-12 | 70934-0264 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb. 7, 2019 | Jan. 31, 2025 | In Use |
70934-0318-03 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 13, 2019 | Oct. 31, 2024 | In Use |
70934-0318-04 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | June 11, 2021 | Oct. 31, 2024 | In Use |
70934-0318-05 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 27, 2021 | Oct. 31, 2024 | In Use |
70934-0318-06 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 1, 2021 | Oct. 31, 2024 | In Use |
70934-0318-10 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | April 4, 2019 | Feb. 28, 2025 | In Use |
82449-0200-03 | 82449-0200 | Ondansetron hydrochloride | Ondansetron hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 30, 2023 | In Use | |
82449-0201-01 | 82449-0201 | Ondansetron hydrochloride | Ondansetron hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Sept. 30, 2023 | In Use | |
50742-0485-05 | 50742-0485 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | May 29, 2020 | In Use | |
61919-0545-05 | 61919-0545 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2014 | In Use | |
61919-0545-06 | 61919-0545 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2014 | In Use | |
61919-0545-10 | 61919-0545 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 1, 2015 | In Use | |
61919-0545-30 | 61919-0545 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan. 1, 2015 | In Use | |
68001-0482-25 | 68001-0482 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan. 25, 2021 | June 30, 2023 | No Longer Used |
68071-3268-01 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use | |
68071-3268-02 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use | |
68071-3268-07 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use | |
68071-3268-03 | 68071-3268 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 23, 2017 | In Use |
Found 10,000 results in 16 milliseconds — Export these results